Enhancing the anti-tumour activity of ¹⁷⁷Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP

Keyphrases

• Antitumor Activity 100%
• Tumor Model 100%
• Radionuclide Therapy 100%
• Somatostatin Receptor 2 (SSTR2) 100%
• PARP Inhibitor (PARPi) 100%
• 177Lu-DOTATATE 100%
• Peptide Receptor Radionuclide Therapy 80%
• Neuroendocrine Tumor 40%
• AR42J Cells 40%
• Talazoparib 40%
• Treatment Options 20%
• Therapeutic Target 20%
• Clinical Evaluation 20%
• In Vitro Study 20%
• Novel Therapeutics 20%
• Focus Formation 20%
• Small Molecules 20%
• Therapy Efficacy 20%
• Tumor Regression 20%
• Therapeutic Action 20%
• Novel Peptide 20%
• DNA Double-strand Breaks 20%
• DNA Damage Repair 20%
• Antitumor Efficacy 20%
• Therapeutic Combinations 20%
• Growth Response 20%
• In Vivo Growth 20%
• γH2AX Foci 20%
• Therapy Regimen 20%
• Growth Properties 20%
• Radiation-induced DNA Damage 20%

Medicine and Dentistry

• Tumor Model 100%
• Antineoplastic Activity 100%
• Tetraxetan 100%
• Lutetium 177 100%
• Somatostatin Receptor 2 100%
• Radionuclide Therapy 100%
• Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase 1 100%
• Oxodotreotide Lu 177 100%
• Peptide Receptor 66%
• Neuroendocrine Tumor 33%
• Talazoparib 33%
• In Vitro 16%
• Clinical Trial 16%
• Tumor 16%
• DNA Repair 16%
• Tumor Regression 16%
• Double-Strand DNA Break 16%
• Treatment Option 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Tetraxetan 100%
• Radioisotope 100%
• Tumor Model 100%
• Lutetium 177 100%
• Somatostatin Receptor 2 100%
• Oxodotreotide Lu 177 100%
• Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase 1 100%
• Receptor 66%
• Neuroendocrine Tumor 33%
• Talazoparib 33%
• Clinical Trial 16%
• Tumor Regression 16%
• Double Stranded DNA 16%